References
- Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost?. Nat Rev Drug Discov. 2017;16:381–2.
- Avorn J. The $2.6 billion pill–methodologic and policy considerations. N Engl J Med. 2015;372:1877–9.
- Babu S, Macklin EA, Simpson E, Mahoney K, Yu H, Walker J, et al. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019. https://doi.org/10.1080/21678421.2019.1672750
- Mathis S, Couratier P, Julian A, Corcia P, Le Masson G. Current view and perspectives in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12:181–4.
- Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open. 2018;8:e018320.
- van Eijk RPA, Nikolakopoulos S, Ferguson TA, Liu D, Eijkemans MJC, van den Berg LH. Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. J Clin Epidemiol. 2018;98:80–8.
- Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20:273–86.
- Barthel FM, Parmar MK, Royston P. How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design – a reanalysis of 4 trials. Trials 2009;10:21.
- Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377:62–70.
- European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis. Available at: https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf; 2016. Accessed October 1, 2019.
- Food Drug Administration Center for Drugs Evaluation Research. Guidance for industry: amyotrophic lateral sclerosis: developing drugs for treatment. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry;2019. Accessed October 1, 2019.
- Schiavone F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, et al. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Trials. 2019;20:264.